Manganese G8 dendrimers targeted to oxidation-specific epitopes: In vivo MR imaging of atherosclerosis

Journal of Magnetic Resonance Imaging

Volumn 41, Issue 3, 2015, Pages 797-805

  Nguyen, Tuyen H ^a   Bryant, Henry ^b   Shapsa, Ari ^a   Street, Hannah ^a   Mani, Venkatesh ^a   Fayad, Zahi A ^a   Frank, Joseph A ^b   Tsimikas, Sotirios ^c   Briley Saebo, Karen C ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

G8 dendrimers; Manganese; Oxidation specific epitopes

Indexed keywords

EPITOPE; MANGANESE G8 DENDRIMER; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OXIDATION SPECIFIC EPITOPE; UNCLASSIFIED DRUG; DENDRIMER; MANGANESE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; IN VIVO STUDY; MACROPHAGE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; ANIMAL; ATHEROSCLEROTIC PLAQUE; C57BL MOUSE; DISEASE MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

ANALYSIS OF VARIANCE; ANIMALS; ATHEROSCLEROSIS; DENDRIMERS; DISEASE MODELS, ANIMAL; EPITOPES; MAGNETIC RESONANCE SPECTROSCOPY; MANGANESE; MICE; MICE, INBRED C57BL; PLAQUE, ATHEROSCLEROTIC;

EID: 84923201906     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24606     Document Type: Article

References (32)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update. Circulation 2012;125:e2-e220.
2. Brautbar A, Ballantyne CM. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol 2011;8:253-265.
3. Finn AV, Chandrashekhar Y, Narula J. Vulnerable plaques: from PROSPECT to prospects. JACC Cardiovasc Imaging 2012;5:334-336.
4. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013;368:2004-2013.
5. Briley-Saebo KC, Cho YS, Tsimikas S. Imaging of oxidation-specific epitopes in atherosclerosis and macrophage-rich vulnerable plaques. Curr Cardiovasc Imaging Rep 2011;4:4-16.
6. Marwick TH, Narula J. Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness? JACC Cardiovasc Imaging 2011;4:1146-1147.
7. Kini AS, Baber U, Kovacic JC, et al. Changes in plaque lipid content after short-term, intensive versus standard statin therapy: the YELLOW Trial. J Am Coll Cardiol 2013;62:21-29.
8. Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res 2012;111:231-244.
9. Miller YI, Choi SH, Wiesner P, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011;108:235-248.
10. van Dijk RA, Kolodgie F, Ravandi A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012;53:2773-2790.
11. Lee S, Birukov KG, Romanoski CE, Springstead JR, Lusis AJ, Berliner JA. Role of phospholipid oxidation products in atherosclerosis. Circ Res 2012;111:778-799.
12. Briley-Saebo KC, Nguyen TH, Saeboe AM, et al. In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes. J Am Coll Cardiol 2012;59:616-626.
13. Briley-Saebo KC, Cho YS, Shaw PX, et al. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J Am Coll Cardiol 2011;57:337-347.
14. Briley-Saebo KC, Shaw PX, Mulder WJ, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008;117:3206-3215.
15. Fang L, Green SR, Baek JS, et al. In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. J Clin Invest 2011;121:4861-4869.
16. Purushothaman KR, Purushothaman M, Levy AP, et al. Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. J Am Coll Cardiol 2012;60:112-119.
17. Patri AK, Simanek E. Biological applications of dendrimers. Mol Pharm 2012;9:341.
18. Nwe K, Milenic DE, Ray GL, Kim Y-S, Brechbiel MW. Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiography. Mol Pharmaceut 2011;9:374-381.
19. Bryant LH Jr, Brechbiel MW, Wu C, Bulte JW, Herynek V, Frank JA. Synthesis and relaxometry of high-generation (G = 5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelates. JMRI J Magn Reson Imaging 1999;9:348-352.
20. Larsen LE, Grant D. General toxicology of MnDPDP. Acta Radiol 1997;38:770-779.
21. Rovetta F, Catalani S, Steimberg N, et al. Organ-specific manganese toxicity: a comparative in vitro study on five cellular models exposed to MnCl(2). Toxicol In Vitro 2007;21:284-292.
22. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol 1999;6:41-53.
23. Amir S, Hartvigsen K, Gonen A, et al. Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. J Lipid Res 2012;53:1316-1326.
24. Nordhoy W, Anthonsen HW, Bruvold M, et al. Intracellular manganese ions provide strong T1 relaxation in rat myocardium. Magn Reson Med 2004;52:506-514.
25. Nordhoy W, Anthonsen HW, Bruvold M, Jynge P, Krane J, Brurok H. Manganese ions as intracellular contrast agents: proton relaxation and calcium interactions in rat myocardium. NMR Biomed 2003;16:82-95.
26. Spencer A, Wilson S, Harpur E. Gadolinium chloride toxicity in the mouse. Hum Exp Toxicol 1998;17:633-637.
27. Shahzad T, Kasseckert SA, Iraqi W, et al. Mechanisms involved in postconditioning protection of cardiomyocytes against acute reperfusion injury. J Mol Cell Cardiol 2013;58:209-216.
28. 2- to everything else. Magn Reson Med 1991;22:183-190.
29. Kojima C, Turkbey B, Ogawa M, et al. Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics. Nanomedicine 2011;7:1001-1008.
30. Merbach AS, Helm L, Toth E. The chemistry of contrast agents in medical magnetic resonance imaging. Hoboken, NJ: John Wiley &Sons; 2013.
31. Albertazzi L, Gherardini L, Brondi M, et al. In vivo distribution and toxicity of PAMAM dendrimers in the central nervous system depend on their surface chemistry. Mol Pharm 2013;10:249-260.
32. Akhtar S, Chandrasekhar B, Attur S et al. On the nanotoxicity of PAMAM dendrimers: SuperfectVR stimulates the EGFR-ERK1/2 signal transduction pathway via an oxidative stress-dependent mechanism in HEK 293 cells. Int J Pharm 2013;448:239-246.